Tagraxofusp, sold under the brand name of
Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It
is composed of catalytic and translocation domains of diphtheria toxin fused
via Met-His linker to a full-length human IL-3. Tagraxofusp was developed by
Stemline Therapeutics Inc. and was approved in December 2018, as the first
therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved
approval after being designed with the title of breakthrough therapy, priority
review, and orphan drug status.
Tagraxofusp
is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm
(BPDCN) in adults and pediatric patients over 2 years old. This treatment
allows an alternative for the previous intense treatment which consisted of
intensive chemotherapy followed by bone marrow transplantation. Some of the
side-effects include fatigue, peripheral edema and weight increase.
Request to Get Free Sample Pages at:
This report
provides details of the drug and the API manufacturers across the 7 major
markets which includes U.S, EU5, and Japan. It includes the overview,
mechanism, regulatory milestones, strategic developments, the historical and
forecasted sales.
Access Detailed Report Summary:
The pipeline analysis of the drug by phase which would
include the product description and development activities including
information about clinical results, designations, collaborations, licensing,
grants, technology and others.
No comments:
Post a Comment